Advertisement
Hepatoprotection via the IL-6/Stat3 pathway
Rebecca Taub
Bristol-Myers Squibb Co., Wallingford, Connecticut, USA
Address correspondence to: Rebecca Taub, Bristol-Myers Squibb Co., PO Box 5100, 5 Research Parkway, Wallingford, Connecticut 06492, USA. Phone: (203) 677-6727; Fax: (203) 677-7569; E-mail: rebecca.taub@bms.com.
Find articles by Taub, R. in: JCI | PubMed | Google Scholar
Published October 1, 2003 - More info
J Clin Invest. 2003;112(7):978–980. https://doi.org/10.1172/JCI19974.
© 2003 The American Society for Clinical Investigation
Acute liver failure is caused by a variety of insults, including viral hepatitis, toxic liver damage by poisons or drugs, and ischemia. The liver is the first line of protection against damage by ingested agents, including xenobiotics and drugs. Hepatic injury by these agents frequently results in both hepatic necrosis and apoptosis (1). It is well known that oxidative damage plays a prominent role in hepatic injury mediated by drugs and poison, whereas viral hepatitis and immune-mediated liver damage are believed to occur largely via activation of the Fas apoptotic death pathway. The link between Fas-mediated damage and the induction of reactive oxygen species (ROS) and oxidative damage has only recently been established (2–6).
Growth factors and cytokines, such as HGF and IL-6, promote hepatic survival by stimulating liver regeneration and providing hepatoprotection in a variety of liver-injury models, including Fas-mediated injury, toxic damage caused by hepatotoxins (such as CCL4), and ischemic liver injury (1, 7–11). These growth factors provide protection against chronic liver injury that ultimately leads to cirrhosis. Part of this protection is mediated by induction of antiapoptotic proteins that regulate the caspase cascade. In this issue of the JCI, Haga and colleagues demonstrate that signal transducer and activator of transcription-3 (Stat3), a key signaling molecule in pathways regulated by IL-6 and related cytokines, blocks apoptotic injury in two ways: induction of anticaspase regulators; and reduction of oxidative injury via upregulation of an antioxidant protein, Ref-1 (12). These findings provide new insights into common mechanisms of hepatoprotection in both Fas-mediated and toxin-mediated acute liver injury and allow predictions about potential therapeutic interventions that could prove beneficial in a variety of liver insults.
-
The IL-6 signal transduction pathway in liver injury and regeneration
IL-6 is a critical proregenerative factor and acute-phase inducer in the liver that also confers resistance to liver injury by hepatic toxins, ischemia, and Fas (Figure 1). Its effects are mediated almost exclusively on hepatocytes within the liver. Although the source of IL-6 within the liver has not been unequivocally established, studies with bone marrow transplantation provide evidence that hepatic Kupffer cells (liver macrophages) are responsible for production of IL-6 in response to liposaccharide or TNF (13). Secreted IL-6 acts on neighboring hepatocytes in a paracrine fashion to stimulate liver regeneration and repair. IL-6 bound to the soluble IL-6 receptor signals via gp130 and Janus kinase-1 (JAK-1), leading to activation of the Stat3 transcription factor and the MAPK signal transduction cascade. IL-6–/– livers induce little Stat3 in response to IL-6 activation during liver regeneration after partial hepatectomy, hepatic injury, or acute-phase induction, suggesting that Stat3 may mediate many of the effects of IL-6 (1, 7–10). Conditional Stat3 knockout mice have been used to show that Stat3 is an important component of the IL-6 response during liver regeneration and the acute-phase response, but Stat3 does not account for all of the effects of IL-6, particularly those that are mediated by MAPK activation (14). Up to 40% of the immediate-early genes induced during liver regeneration are regulated at least in part by IL-6, and a significant subset of these are also regulated by Stat3.
Figure 1Model for IL-6/Stat3 signaling pathway. IL-6 binds to its soluble receptor, sIL-6r, which binds to the gp130 receptor, resulting in the activation of Janus kinase (JAK). This leads to activation of the MAPK pathway and activation of Stat3 by tyrosine (Y) phosphorylation. Dimerized Stat3 is able to translocate into the nucleus and activate gene transcription. In the liver, this process promotes liver regeneration, the acute-phase response, and hepatoprotection against Fas and toxic damage. P, phosphate.
-
Modulation of Stat3 levels in liver cells points to its critical role in hepatocyte survival
Stat3 is a vital, ubiquitously expressed protein that is activated by a number of ligands in addition to IL-6 (15, 16). It has important roles in mitogenesis and antiapoptosis. Stat3 has been shown to be involved in the transcriptional upregulation of many genes, not only acting by direct DNA binding, but acting in some cases as a coactivator of transcription factors such as activator protein-1 and hepatocyte nuclear factor-1 (17). Stat3 knockout results in early embryonic lethality, but conditional knockouts provide useful tools to examine the actions of Stat3 in specific tissues. In the study by Haga et al. (12), two animal models were used to examine the effects of Stat3 modulation in Fas-mediated liver injury: mice injected with adenoviruses expressing constitutively active Stat3 and other proteins; and mice with hepatocyte-specific Stat3 gene deletions. Adenoviruses injected intravenously normally home to the liver, infecting more than 80% of hepatocytes and allowing for expression of encoded proteins. Haga et al. demonstrate that constitutively active Stat3 provided protection against Fas-mediated liver injury, and that Stat3 deficiency led to Fas sensitivity. The antiapoptotic proteins FLIP, Bcl-2, and Bcl-XL, which block caspase activation, are elevated in IL-6–treated livers (9). Haga and colleagues report here that these proteins were also elevated in Stat3-overexpressing livers, providing evidence that Stat3 mediates the major antiapoptotic effects of IL-6 (Figure 2). Whereas IL-6–mediated elevation of antiapoptotic proteins is largely posttranscriptional (9), mRNA for these proteins was elevated in the Stat3-overexpressing livers (12). This difference could be due to the massive overexpression of Stat3 and the fact that adenovirus infection confers a degree of transcriptional induction not seen in normal mice.
Figure 2Proposed model for the actions of IL-6 and Stat3 that result in hepatoprotection against Fas activation. Interaction of FasL with its receptor activates the caspase cascade that is blocked by IL-6 and Stat3 through the upregulation of FLIP, Bcl-2, and Bcl-XL. Fas activation also generates an oxidative stimulus that is blocked by the upregulation of Ref-1. FADD, Fas-associated death domain; Rac1, RAS-related C3 botulinum toxin substrate 1; Apaf1, apoptotic protease activating factor; Bax, Bcl2-associated X protein; Bid, BH3-interacting domain death agonist.
This mechanistic evaluation was taken to another level by the demonstration that not only anticaspase agents, but also the antioxidant N-acetyl cysteine, were able to provide some protection against the effect of Stat3 deficiency on Fas-mediated apoptosis (12). Having identified ROS as a component of Fas-mediated liver injury, Haga et al. identified an endogenous antioxidant, Ref-1, as a target of Stat3. Expression of Ref-1 provided hepatoprotection, strongly suggesting that Ref-1 is a critical component of Stat3-mediated hepatoprotection. Ref-1, a dual-function protein upregulated by increases in ROS, is an endonuclease in the base excision repair pathway and a reducing agent that facilitates the DNA-binding properties of redox-sensitive transcription factors (18–21). Ref-1 is able to suppress ROS generation and hepatic apoptosis (Figure 2).
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)